

T2 Biosystems, Inc.  
Form 8-K  
September 07, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 31, 2018**

**T2 BIOSYSTEMS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**001-36571**  
**(Commission**

**20-4827488**  
**(IRS Employer**

**of incorporation)**

**File Number)**

**Identification Number)**

**101 Hartwell Avenue, Lexington, Massachusetts 02421**

Edgar Filing: T2 Biosystems, Inc. - Form 8-K

**(Address of principal executive offices, including Zip Code)**

**(781) 761-4646**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement.**

On August 31, 2018, the registrant and Columbus Day Realty, Inc. (the Landlord ) entered into Amendment No. 4 to Commercial Lease (the Lease Amendment ) to the lease agreement dated May 6, 2013 (as subsequently amended, the Lease ) for its manufacturing facility located at 231 Andover Street, Wilmington, Massachusetts (the Premises ).

The Lease Amendment extends the term of the Lease from December 31, 2018 to December 31, 2020. Beginning on January 1, 2019 and ending on December 31, 2019, the registrant is obligated to pay the Landlord rent at the rate of Ten Dollars (\$10.00) per square foot for a total base rent of \$75,700. The registrant's base rent will increase to Eleven Dollars (\$11.00) per square foot beginning on January 1, 2019 and ending on December 31, 2020 for a total base rent of \$83,270.

The foregoing description of the Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
10.1	<u>Fourth Amendment to Lease, dated August 31, 2018</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 7, 2018

**T2 BIOSYSTEMS, INC.**

By: /s/ John McDonough  
John McDonough

President and Chief Executive Officer